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Berberine is an isoquinoline alkaloid found in some plants and has many 
bioactivities including anti-microbial, lipid- and glucose-lowering, anti-cancer, 
anti-inflammatory, etc. However, there is limited knowledge about berberine’s 
effects on development and locomotive activity. Herein, in vivo studies were 
conducted to determine these effects of berberine using Caenorhabditis elegans as 
an in vivo model. Treatment of berberine at 50 μM starting at L1 stage significantly 
retarded the growth rate of nematodes, and reduced the length, width and moving 
speed of worms by 19%, 12% and 29%, respectively, compared to the control. In 
addition, triglycerides (TG) and protein content in worms was reduced by 23% and 
28%, respectively, after berberine treatment from L1 stage compared with the 
control group. However, no significance was observed when berberine was treated 
from young adult stage. These findings suggest that berberine has effects on 
development in C. elegans. 
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Berberine is an isoquinoline alkaloid found in several plants such as Berberis 
vulgaris (barberry), Berberis aristata (tree turmeric), and Coptis chinensis (Chinese 
goldthread)1. There are also dietary supplements containing berberine processed 
from these plants. It has been proven that berberine has health benefits, including 
anti-microbial, lipid- and glucose-lowering, anti-cancer, anti-inflammatory, 
reducing cardiovascular diseases, and improving nervous system, etc2–10. There are 
limited reports of the effects of berberine on locomotion, including its protective 
role for morphine-, cocaine- and ethanol-induced adverse effects and its stimulation 
effects on locomotor activity in Drosophila melanogaster11–15. However, studies on 
the effects of berberine on growth and locomotive activity, especially in vivo studies, 
are still inadequate.  
Caenorhabditis elegans is a small free-living nematode found in temperate 
soil environments, which has been widely applied in many scientific researches 
focusing on obesity, aging, and development16–19. This animal model has many 
advantages, such as a small body size, short life span, large brood size, and low 
maintenance cost20. In addition to its rapid life cycle20, every stage in its life cycle 
has easily distinguishable features20. Locomotion behavior of C. elegans, as an 
indicator of activity, can be measured with a tracking system21. Furthermore, it has 
many development- and locomotion-related genes, which are orthologs of human 
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genes21–24. Thus, C. elegans was utilized as an in vivo model in the current study to 






2.1 Caenorhabditis elegans 
2.1.1 Introduction 
C. elegans is a small free-living nematode found in temperate soil environments 
worldwide16,17. It was first introduced as a genetic model to study developmental 
biology and neurobiology by Sydney Brenne in 1960s16,17. C. elegans is now widely 
applied in research involving obesity, aging, development, locomotion behavior, 
and neurodegenerative disorders19,25.  
Compared with traditional animal models, this eukaryotic and multi-organ 
animal model possesses many advantages. It has a small body size, short life span, 
and large brood size20. At the same time, C. elegans is inexpensive and convenient 
to maintain20. Furthermore, it has a completely sequenced and well-annotated 
genome, which encodes over 65% of characterized human disease-related genes25. 
Moreover, it has many mutants available, which could be easily utilized for 
mechanistic studies26. And research using C. elegans does not require approval 
from the Institutional Animal Care and Use Committees25. 
 
2.1.2 Life Cycle 
The life cycle of C. elegans consists of four larval stages (L1, L2, L3, and L4 stage) 
and adulthood27. C. elegans embryogenesis takes around 16 hours at 20 oC. L1 
larvae are hatched out from eggs and take around another 16 hours to develop into 
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the L2 stage. L2, L3 and L4 stages last around 12 hours long, respectively20. Each 
stage ends with a period called lethargus, during which a new cuticle of nematodes 
is made28. Lethargus ends with molting of the old cuticle. Approximately 12 hours 
after molting of nematodes at the L4 stage20, C. elegans at adulthood begins to 
produce progeny, which will last 5-6 days. However, when L2 larvae lack food or 
are crowded, they will develop into an alternative life cycle29 and molt into an 
alternative L3 stage called the “dauer” stage30. At this stage, the dauer larvae have 
enhanced resistance against environmental stresses, can survive for several months, 
and continue to develop as slightly different L4 larvae if they are provided with 
enough food20. 
 
2.1.3 Locomotion Behavior 
There are 302 neurons of 959 somatic cells in nematodes. C. elegans shares highly 
conserved neurotransmitter receptors, neurotransmitter synthesis and release 
pathways, heterotrimeric guanosine-5'-triphosphate (GTP) binding proteins 
coupled second messenger pathways, and major genes involved with mammals23,31. 
Therefore, this animal model has been widely applied in research to study basic 
mechanisms underlying drug-induced behaviors by investigating its locomotion 
behavior23,24. 75 motoneurons of 302 neurons control body wall muscles, which 
provide thrust for C. elegans during locomotion32. The regular contraction and 
relaxation of muscle cells innervated by motoneurons in C. elegans lead to its 
movement20,32.  
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C. elegans locomotes in an undulatory way33,34. It generates thrust by 
propagating the bending of its body in the direction of locomotion34. When 
nematodes move on the surface of the agar, the routes they crawled through will 
produce typical S shapes. Without the consideration of steering, the locomotion 
behavior of C. elegans could be generally divided into four patterns: forward 
locomotion, backward locomotion, dwelling (nondirectional body bends), and 
quiescence28,35–37. Each of these patterns could appear randomly and persist for a 
while during nematodes’ locomotion38–40. Such locomotion behavior can be 
recorded and analyzed with a tracking system21. 
 
2.1.4 Uptake of Compounds into C. elegans 
C. elegans is actively utilized as a research model to determine activities of various 
compounds. There are mainly three ways to deliver compounds to C. elegans: [1] 
mix compounds with nematodes’ bacterial food source, [2] directly spread 
compounds onto the surface of nematode growth medium (NGM) agar plates, and 
[3] add compounds into nematodes’ liquid medium41. However, it is worth noting 
that the final concentration of dimethyl sulfoxide (DMSO) solution in nematodes’ 
medium higher than 0.6% (v/v) will shorten the life span of C. elegans42. 
Compounds can be taken up by C. elegans via three ways: ingestion, 
through the cuticle, and exposed sensory neuronal cilia43. During ingestion, 
appropriate food sources will be recognized and chosen by chemosensory neurons 
and then consumed via aspiration by pharynx of C. elegans. Then compounds will 
be absorbed by intestinal cells and distributed throughout the worm body43. The 
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cuticle of C. elegans can also allow diffusion of some compounds into and out of 
nematodes through a permeability barrier established by hypodermis44. Lastly, 





Berberine is an isoquinoline alkaloid found in plants such as Berberis vulgaris 
(barberry), Berberis aristata (tree turmeric), and Coptis chinensis (Chinese 
goldthread)1. The main biological properties of berberine reported are anti-
microbial, lipid- and glucose-lowering, anti-cancer, and anti-inflammatory 
effects1,9,46. In addition, berberine has been reported to have beneficial effects on 
cardiovascular system1 and nervous system2. 
There are reports of berberine’s effects at the cellular level, particularly in 
hepatocytes, macrophages, endothelial cells, adipocytes, and myocytes46. Berberine 
mainly protected them from the adverse effects of atherosclerosis47–50 and improved 
glucose utilization in adipocytes and myocytes51. 
In addition, in vivo and clinical studies of berberine have reported on its 
effects on hypercholesterolemia, diabetes, and obesity46. However, based on the 
evidence available to date, additional well-designed trials to confirm the safety and 




2.2.2 Effects of Berberine on Cytotoxicity 
Research on the cytotoxicity of berberine generally used bacterial colony and 
mammalian cell lines. Several studies concluded that berberine could inhibit the 
growth of different species of bacteria and change their structures3,4, which proves 
that berberine has anti-microbial effects. Others reported that berberine inhibited 
the growth of many cancer cells, originated from prostate5, neuroblastoma52, lung6, 
cervix7, breast8, and others10. This also supports the anti-cancer properties of 
berberine. 
 
2.2.3 Effects of Berberine on Locomotion 
Previously it was reported that berberine could prolong life span and stimulate 
locomotor activities of Drosophila melanogaster11. In this study, the vertical 
climbing assay was used to measure the ability of Drosophila to climb the wall of 
a vial when startled11, assessing ability to complete a strenuous activity53. Berberine 
stimulated vertical climbing of flies by 39% over the control in the climbing height 
indicator11. 
In addition, the effects of berberine on locomotion were investigated when 
studying its inhibition of morphine-, cocaine- and ethanol-induced adverse effects. 
Berberine could attenuate the expression of sensitization to locomotor stimulant 
effects of morphine, cocaine, and ethanol12–15. However, research focusing on the 




2.2.4 Effects of Berberine on Lipid Metabolism 
Berberine has been studied on its lipid-lowering effect both in cellular and animal 
models50,54–60. Treatment with berberine reduced plasma total cholesterol and non-
HDL (high-density lipoprotein) cholesterol levels in atherogenic diet-fed rats and 
high-fat diet-fed mice56,57,59,60. Oral administration of berberine in 
hypercholesterolemic patients also reduced serum cholesterol, triglycerides, and 
LDL (low-density lipoprotein) cholesterol levels50. Berberine also inhibited hepatic 
fat accumulation in mice and attenuated hepatic steatosis in hamsters54,59. It has 
been concluded that berberine acts in the liver to regulate lipid utilization54. These 
findings support that berberine has therapeutic potential to treat metabolic 
dysfunctions under nutritional overloads, such as fatty liver diseases and type 2 
diabetes, and is suggested to be a new hypolipidemic drug. 
 
2.2.5 The Role of AMP-activated Protein Kinase in Berberine’s Effects 
A number of studies reported that the major cellular process in which berberine is 
effective involves AMP-activated protein kinase (AMPK)61, which plays a critical 
role in cellular energy homeostasis61. The activation of AMPK by berberine led to 
its antidiabetic properties62–65. In addition, this can also demonstrate that 
berberine’s potential in inhibiting aging-related diseases via AMPK cellular kinase 
activation66–68. AMPK also possesses significance in physical activity69,70, 





C. elegans is a well-established in vivo model for studying the beneficial effects of 
food bioactive compounds. Berberine has shown to possess anti-microbial, lipid- 
and glucose-lowering, anti-cancer, and anti-inflammatory properties. However, 
research on its effects on exercise and growth is not comprehensive yet. Therefore, 
the goal of the current research was to determine the role of berberine on growth 




MATERIALS AND METHODS 
 
3.1 Materials 
Berberine chloride (97%), commercial kits for triglycerides (Infinity™ 
Triglycerides Liquid Stable Reagent), and protein (Pierce™ BCA Protein Assay 
Kit) quantification were purchased from Thermo Fisher Scientific Chemicals, Inc. 
(Waltham, MA). Chemicals used for Caenorhabditis elegans maintenance 
including agar, peptone, and LB broth were purchased from Fisher Scientific, Inc. 
(Pittsburgh, PA). Ampicillin, carbenicillin, and fluorodeoxyuridine (FUdR) were 
purchased from Sigma-Aldrich Co. (St. Louis, MO). Escherichia coli (E. coli) 
OP50 and C. elegans wild isolate (N2) were obtained from Caenorhabditis Genetics 
Center (Minneapolis, MN).  
 
3.2 C. elegans Maintenance and Treatment 
C. elegans was maintained as previously reported26. E. coli OP50 was prepared as 
a food source. Berberine stock solutions were prepared in dimethyl sulfoxide 
(≥99.9%, DMSO). For treatment starting from the L1 stage, synchronized L1 C. 
elegans was treated with DMSO (0.1% v/v final) as vehicle or 50 mM berberine 
stock solutions (0.1% v/v final) in S Medium for 48 hours at 20 oC. For treatment 
starting from the young adulthood stage, firstly synchronized L4 C. elegans was 
treated with 6 mM FUdR solution (2% v/v final). And then, worms on the first day 
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of adulthood were treated with DMSO (0.1% v/v final) as vehicle or 50 mM 
berberine stock solutions (0.1% v/v final) in S Medium for 48 hours at 20 oC.  
 
3.3 Growth Rate, Body Size and Locomotive Activity Assay 
For the growth rate assay, numbers of C. elegans at different larval stages were 
counted after 48-hour treatment. Results were presented as percentages of C. 
elegans numbers at different larval stages to the total. 
Body size and locomotive activity of C. elegans were measured with a 
WormLab tracking system73 (MBF Bioscience, Williston, VT). C. elegans were 
transferred onto a low-peptone NGM (nematode growth medium) plate freshly 
seeded with E. coli OP50 solution in LB broth. The worms were allowed to move 
around freely for 10 minutes and become acclimated to light for another 10 minutes 
before recording. Each video recording of C. elegans for 1 minute was analyzed 
with a WormLab software (MBF Bioscience version 3.1.0, Williston, VT) for 
average moving speed, worm length, and worm width.  
 
3.4 Triglyceride and Protein Quantification 
After the 48-hour treatment, C. elegans was collected and washed five times with 
Milli-Q water to eliminate E. coli and berberine. C. elegans was then dissolved in 
Tween 20 (0.05% v/v), sonicated, and measured for triglycerides (TG) and protein 
content with the commercial kits as described before73. Protein content was used to 
normalize TG levels. 
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3.5 Statistical Analysis 
Statistical analysis was performed through Chi-square (and Fisher’s exact) test and 
t-tests (and nonparametric tests) using GraphPad Prism (GraphPad Software 
version 8.4.2, San Diego, CA) or one-way ANOVA (Tukey’s test for multiple 
comparisons) using Statistical Analysis System (SAS Institute version 9.4, Cary, 






4.1 Berberine Inhibited Growth of Caenorhabditis elegans 
There were 91% of the worms at the L4 stage, 3% at the L3 stage, 5% at the L2 
stage, and 1% at the L1 stage in the control group after 48 hours of incubation 
(Figure 4.1). However, only 67% of the worms reached the L4 stage, 19% at the L3 
stage and 14% at the L2 stage in the 50 μM berberine group. This suggests that the 
growth rate was significantly slowed after 48 hours of treatment of berberine at 50 
μM compared to the control (p = 0.0001). 
 
Figure 4.1 Berberine significantly slowed the growth rate of C. elegans. 
Synchronized L1 worms were treated with control (0.1% DMSO) or berberine (50 
μM) for 48 hours at 20 oC. The growth rate was scored as percentages of worms’ 
numbers at different developmental stages to the total. Results are presented as 
means ± S.E. (n = 4 plates, each plate contained ≈ 50 worms). a, b Means with 
different letters are significantly different (p < 0.05). 
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4.2 Effects of Berberine on Body Size and Locomotive Activity 
When berberine was treated from L1 stage, the length of worms was significantly 
decreased by 19% compared to the control (p < 0.0001, Figure 4.2A). Similarly, 
the width of the worms in the 50 μM berberine treated group was also decreased 
significantly by 12% compared with the control group (p < 0.0001, Figure 4.2B). 
These are consistent to the result of retarded growth rate by berberine in Figure 4.1. 
 
 
Figure 4.2 Effects of berberine treatment during development on body size 
and locomotive activity of C. elegans. Synchronized L1 worms were treated with 
control (0.1% DMSO) or berberine (50 μM) for 48 hours at 20 oC. Body size, 
including worm length (A) and width (B), and locomotive activity, presented as 
average moving speed (C), were measured with the WormLab tracking system. 
Results are presented as means ± S.E. (n = 350-400 worms). a, b Means with 
different letters are significantly different (p < 0.05). 
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Treatment of 50 μM berberine significantly reduced the moving speed of 
the worms by 29% compared to the control (p < 0.0001, Figure 4.2C), which may 
also be due to the retarded growth rate by the berberine treatment. Taken together, 
it is suggested that both the body size and moving speed of worms were 
significantly reduced after 48 hours of treatment of berberine at 50 μM. 
 
Figure 4.3 Effects of berberine on body size and locomotive activity treated 
from young adulthood in C. elegans. Synchronized worms on the first day of 
adulthood were treated with control (0.1% DMSO) or berberine (50 μM) for 48 
hours at 20 oC. Body size, including worm length (A) and width (B), and 
locomotive activity, presented as average moving speed (C), were measured with 
the WormLab tracking system. Results are presented as means ± S.E. (n = 40-80 
worms). 
 
Next, we treated berberine after nematodes were fully grown. There was no 
significant difference in worm length between worms of the control and berberine 
groups (Figure 4.3A). However, there was a significant reduction of body width by 
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berberine treatment over the control, 6% reduction with p = 0.0199 (Figure 4.3B). 
This suggests that berberine has small, but significant effects on body size of C. 
elegans at the young adulthood stage. There was no difference in moving speed 
between treatments (Figure 4.3C).  
 
4.3 Effects of Berberine on Triglycerides and Protein Content 
The triglycerides (TG) level in worms treated with 50 μM berberine from L1 stage 
was significantly reduced by 23% compared with the control group (p = 0.0004, 
Figure 4.4A). Similarly, the content of protein was also significantly reduced by 
berberine treatment, 28%, compared to the control (p < 0.0001, Figure 4.4B). The 
lower level of the TG and protein by berberine treatment seen in Figure 4.4 may be 
due to the retarded growth rate in C. elegans74,75. 
 
Figure 4.4 Effects of berberine on triglycerides (TG, A) and protein (B) content 
treated from L1 stage in C. elegans. Synchronized L1 worms were treated with 
control (0.1% DMSO) or berberine (50 μM) for 48 hours at 20 oC. TG content was 
measured and normalized by protein levels. Results are presented as means ± S.E. 
(n = 5 plates, each plate contained ~ 1,000 worms). a, b Means with different letters 
are significantly different (p < 0.05). 
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When nematodes were treated with berberine from young adulthood, there 
was no significant difference in TG content between control and berberine groups 
(Figure 4.5). And no significant difference was observed in protein levels between 
two groups as well. This suggests that berberine has no effect on fat accumulation 
in C. elegans. 
 
Figure 4.5 Effects of berberine on triglycerides (TG) content treated from 
young adulthood in C. elegans. Synchronized worms on the first day of adulthood 
were treated with control (0.1% DMSO) or berberine (50 μM) for 48 hours at 20 
oC. TG content was measured and normalized by protein levels. Results are 






Berberine, an isoquinoline alkaloid found in several plants, has been reported to 
have many beneficial effects1,2,9,46. In the current study, treatment of berberine 
during growth period significantly retarded the growth of Caenorhabditis elegans, 
accompanied with reduced body size, reduced moving speed, and reduced both 
triglycerides (TG) and protein content of worms, while no significant effects were 
observed when berberine was treated after worms were fully grown. 
Normally, L1 larvae will take around 40 hours to develop into the L4 stage. 
When facing unfavorable environmental condition, larvae of nematodes at the L2 
stage can arrest development themselves by forming dauer larvae29,30. In addition, 
C. elegans larvae were reported to be able to reversibly arrest development at the 
L1 stage, which was called “L1 arrest”76. These are two kinds of naturally occurring 
growth inhibition without any treatment, which are similar to the results observed 
in the current study. 
The most direct reason for the above two phenomena is the starvation of 
worms29,30,76. High density and temperature are also common reasons for dauer 
arrest76. As for our study, because worms of both the control and treatment groups 
were provided with almost the same nematode density and temperature, one of the 
possible reasons is that berberine suppressed the worms’ food intake. 
What’s more, insulin-like signaling, phosphatase and tensin homolog 
(PTEN), liver kinase B1 (LKB1), AMPK, and fatty acid biosynthesis in C. elegans 
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have already been reported to be involved in development22,76. It was reported that 
reduced insulin-like signaling would induce developmental quiescence77. At the 
same time, AMPK would interact with insulin-like signaling76,78. In C. elegans, 
mutation of aak-2, which is a homologue of AMPK and evolutionarily conserved 
in both C. elegans and mammals79, was proved to result in an L1 arrest-defective 
phenotype76,80. Besides, C. elegans orthologues of LKB1 and AMPK could 
cooperate to establish cell cycle quiescence in the germline stem cell population as 
well when insulin-like signaling was reduced22. Combined with the reports that 
AMPK is critical in many properties of berberine mentioned before61, AMPK could 
also play an important role in the retarded growth rate caused by berberine here.  
Accompanied with the retarded growth rate, worms’ body size, moving 
speed, and both TG and protein content were reduced after treatment of berberine. 
The reduction of body size was consistent with the developmental delay in C. 
elegans. And it is known that worms deposit TG after they are grown18,81. Thus, the 
lower TG content was accompanied with retarded growth rate. In addition, the 
lower level of protein in worms may be due to the influence of berberine on the 
metabolic activities in C. elegans74,75. 
One previous study using Drosophila melanogaster as a model reported the 
stimulation effects of berberine on locomotor activities11. However, we did not 
observe any significant changes of activity by berberine treatment, which means 
that 50 μM berberine cannot stimulate locomotive activity in C. elegans. It is 
possible that the dosage of berberine treated in this study was lower than the 
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Drosophila study (1 mM)11. Higher doses of berberine could be utilized to conduct 
locomotive activity studies in C. elegans in the future. 
Berberine has been reported to have lipid-lowering effect54,56,57,59,60. 
However, the reduction of TG content in the current study was observed when 
berberine was treated during worms’ growth period only, but not after worms were 
fully grown. Based on our preliminary experiment using fat models (worms treated 
with glucose from L4 stage) of C. elegans82, berberine still have no effect on TG 
content. In addition, berberine at higher concentration (100, 200, and 300 μM) 
significantly reduced protein content without changing the TG content. This 
suggests that berberine has no effect on lipid metabolism in this model. Possible 
reasons may be the different stages of the life cycle of nematodes used in this study 
and the comparatively lower dosage of berberine treated compared to other in vivo 
studies54,56,57,59,60. 
To conclude, the current results suggest the inhibitory effect of berberine on 
the growth of C. elegans. Its body size and moving speed were significantly reduced 
when berberine was treated during worms’ growth period. This is the first study to 
demonstrate the influence of berberine on the development of C. elegans, which 






In this current research, berberine has effects in C. elegans on development as seen 
in growth rate, body size, locomotion, protein, and triglycerides. However, the 
mechanisms of these effects have not been determined. Further researches could be 
conducted to provide more comprehensive evidence for berberine’s effects. 
To complement current research, future work could be carried out from 
three aspects. First, the food intake assay of C. elegans at the L1 stage treated by 
berberine could be conducted. This could be one possible reason leading to the 
retard growth rate29,30,76. Secondly, AMPK is a potential critical pathway of 
berberine’s effects on development of C. elegans22,61,76, thus using different 
mutants with gene knocked out26, such as aak-2 (homolog of AMPK), can be 
utilized to determine its effects. Lastly, the effects of berberine at higher doses, 
particularly on the locomotive activity in C. elegans, need to be determined. 
In conclusion, the current research showed that berberine could 
significantly delay the development in C. elegans. These findings could provide 




1. Imanshahidi M, Hosseinzadeh H. Pharmacological and therapeutic effects of 
Berberis vulgaris and its active constituent, berberine. Phytotherapy research. 
2008;22(8):999–1012. 
2. Imenshahidi M, Hosseinzadeh H. Berberis Vulgaris and Berberine: An Update 
Review. Phytotherapy Research. 2016;30(11):1745–1764. doi:10.1002/ptr.5693 
3. Stermitz FR, Tawara-Matsuda J, Lorenz P, Mueller P, Zenewicz L, Lewis K. 5 
‘-Methoxyhydnocarpin-D and Pheophorbide A: Berberis Species Components 
that Potentiate Berberine Growth Inhibition of Resistant Staphylococcus aureus. 
Journal of natural products. 2000;63(8):1146–1149. 
4. Kaneda Y, Torii M, Tanaka T, Aikawa M. In vitro effects of berberine sulphate 
on the growth and structure of Entamoeba histolytica, Giardia lamblia and 
Trichomonas vaginalis. Annals of Tropical Medicine & Parasitology. 
1991;85(4):417–425. 
5. Choi MS, Oh JH, Kim SM, Jung HY, Yoo HS, Lee YM, Moon DC, Han SB, 
Hong JT. Berberine inhibits p53-dependent cell growth through induction of 
apoptosis of prostate cancer cells. International journal of oncology. 
2009;34(5):1221–1230. 
6. Katiyar SK, Meeran SM, Katiyar N, Akhtar S. p53 cooperates berberine‐
induced growth inhibition and apoptosis of non‐small cell human lung cancer 
cells in vitro and tumor xenograft growth in vivo. Molecular Carcinogenesis: 
Published in cooperation with the University of Texas MD Anderson Cancer 
Center. 2009;48(1):24–37. 
7. Mahata S, Bharti AC, Shukla S, Tyagi A, Husain SA, Das BC. Berberine 
modulates AP-1 activity to suppress HPV transcription and downstream signaling 
to induce growth arrest and apoptosis in cervical cancer cells. Molecular cancer. 
2011;10(1):39. 
8. Kim J, Yu J-H, Ko E, Lee K-W, Song A, Park SY, Shin I, Han W, Noh D. The 
alkaloid Berberine inhibits the growth of Anoikis-resistant MCF-7 and MDA-
MB-231 breast cancer cell lines by inducing cell cycle arrest. Phytomedicine. 
2010;17(6):436–440. 
9. Tang J, Feng Y, Tsao S, Wang N, Curtain R, Wang Y. Berberine and Coptidis 
Rhizoma as novel antineoplastic agents: A review of traditional use and 




10. Mantena S, Sharma S, Katiyar S. Berberine inhibits growth, induces G1 arrest 
and apoptosis in human epidermoid carcinoma A431 cells by regulating Cdki–
Cdk-cyclin cascade, disruption of mitochondrial membrane potential and cleavage 
of caspase 3 and PARP. Carcinogenesis. 2006;27(10):2018–2027. 
11. V.,Navrotskaya V, G.,Oxenkrug, I.,Vorobyova L, P.,Summergrad. Berberine 
Prolongs Life Span and Stimulates Locomotor Activity of Drosophila 
melanogaster. American Journal of Plant Sciences. 2012;2012(07):1037–1040. 
doi:10.4236/ajps.2012.327123 
12. Nassiri-Asl M, Hosseinzadeh H, Mortazavi SR. Effects of Berberis vulgaris 
fruit extracts and its active component, berberine, on morphine dependence, 
hypnosis and locomotor activity in mice. Pharmacologyonline. 2007;1:190–202. 
13. Bhutada P, Mundhada Y, Bansod K, Rathod S, Hiware R, Dixit P, Umathe S, 
Mundhada D. Inhibitory effect of berberine on the motivational effects of ethanol 
in mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 
2010;34(8):1472–1479. 
14. Yoo J-H, Yang E-M, Cho J-H, Lee J-H, Jeong S, Nah S-Y, Kim H-C, Kim K-
W, Kim S-H, Lee S-Y. Inhibitory effects of berberine against morphine-induced 
locomotor sensitization and analgesic tolerance in mice. Neuroscience. 
2006;142(4):953–961. 
15. Lee B, Yang CH, Hahm D-H, Choe ES, Lee H-J, Pyun K-H, Shim I. 
Inhibitory effects of Coptidis rhizoma and berberine on cocaine-induced 
sensitization. Evidence-Based Complementary and Alternative Medicine. 
2009;6(1):85–90. 
16. Brenner S. The worm’s turn. Current Biology. 2002;12(21):R713. 
doi:10.1016/s0960-9822(02)01241-1 
17. Félix M-A, Duveau F. Population dynamics and habitat sharing of natural 
populations of Caenorhabditis elegans and C. briggsae. BMC Biology. 
2012;10(1):59. doi:10.1186/1741-7007-10-59 
18. Shen P, Yue Y, Park Y. A living model for obesity and aging research: 
Caenorhabditis elegans. Critical Reviews in Food Science and Nutrition. 
2017;58(5):00–00. doi:10.1080/10408398.2016.1220914 
19. Zheng J, Greenway FL. Caenorhabditis elegans as a model for obesity 
research. International Journal of Obesity. 2012;36(2):186–194. 
doi:10.1038/ijo.2011.93 
20. Corsi AK, Wightman B, Chalfie M. A Transparent Window into Biology: A 
Primer on Caenorhabditis elegans. Genetics. 2015;200(2):387–407. 
doi:10.1534/genetics.115.176099 
 24 
21. Shen P, Yue Y, Sun Q, Kasireddy N, Kim K, Park Y. Piceatannol extends the 
lifespan of Caenorhabditis elegans via DAF‐16. BioFactors. 2017;43(3):379–387. 
doi:10.1002/biof.1346 
22. Narbonne P, Roy R. Inhibition of germline proliferation during C. elegans 
dauer development requires PTEN, LKB1 and AMPK signalling. Development. 
2006;133(4):611–619. doi:10.1242/dev.02232 
23. Feng Z, Li W, Ward A, Piggott BJ, Larkspur ER, Sternberg PW, Xu XZS. A 
C. elegans Model of Nicotine-Dependent Behavior: Regulation by TRP-Family 
Channels. Cell. 2006;127(3):621–633. doi:10.1016/j.cell.2006.09.035 
24. Ward A, Walker VJ, Feng Z, Xu XZS. Cocaine Modulates Locomotion 
Behavior in C. elegans. PLoS ONE. 2009;4(6):e5946. 
doi:10.1371/journal.pone.0005946 
25. Shen P, Yue Y, Zheng J, Park Y. Caenorhabditis elegans: A Convenient In 
Vivo Model for Assessing the Impact of Food Bioactive Components on Obesity, 
Aging, and Alzheimer’s Disease. Annual review of food science and technology. 
2017;9(1):1–22. doi:10.1146/annurev-food-030117-012709 
26. Stiernagle T. Maintenance of C. elegans. WormBook. 2006:1–11. 
doi:10.1895/wormbook.1.101.1 
27. Wood WB. The Nematode Caenorhabditis Elegans. Cold Spring Harbor 
Laboratory; 1988. https://books.google.com/books?id=LTEPi6VlZZkC 
28. Raizen DM, Zimmerman JE, Maycock MH, Ta UD, You Y, Sundaram MV, 
Pack AI. Lethargus is a Caenorhabditis elegans sleep-like state. Nature. 
2008;451(7178):569–572. 
29. Hu PJ. Dauer. 2018. (WormBook: The Online Review of C. elegans Biology 
[Internet]). 
30. Golden JW, Riddle DL. The Caenorhabditis elegans dauer larva: 
developmental effects of pheromone, food, and temperature. Developmental 
biology. 1984;102(2):368–378. 
31. Bargmann CI. Neurobiology of the Caenorhabditis elegans genome. Science. 
1998;282(5396):2028–2033. 
32. Gjorgjieva J, Biron D, Haspel G. Neurobiology of Caenorhabditis elegans 
Locomotion: Where Do We Stand? BioScience. 2014;64(6):476–486. 
doi:10.1093/biosci/biu058 
33. Burr A, Robinson AF. Locomotion behaviour. Nematode behaviour. 2004:25–
62. 
 25 
34. Gray J, Lissmann HW. The locomotion of nematodes. Journal of 
Experimental Biology. 1964;41(1):135–154. 
35. Gray JM, Hill JJ, Bargmann CI. A circuit for navigation in Caenorhabditis 
elegans. Proceedings of the National Academy of Sciences. 2005;102(9):3184–
3191. doi:10.1073/pnas.0409009101 
36. Stephens GJ, Mesquita MB de, Ryu WS, Bialek W. Emergence of long 
timescales and stereotyped behaviors in Caenorhabditis elegans. Proceedings of 
the National Academy of Sciences. 2011;108(18):7286–7289. 
doi:10.1073/pnas.1007868108 
37. Gallagher T, Bjorness T, Greene R, You Y-J, Avery L. The geometry of 
locomotive behavioral states in C. elegans. PloS one. 2013;8(3). 
38. Fujiwara M, Sengupta P, McIntire SL. Regulation of Body Size and 
Behavioral State of C. elegans by Sensory Perception and the EGL-4 cGMP-
Dependent Protein Kinase. Neuron. 2002;36(6):1091–1102. doi:10.1016/s0896-
6273(02)01093-0 
39. Flavell SW, Pokala N, Macosko EZ, Albrecht DR, Larsch J, Bargmann CI. 
Serotonin and the Neuropeptide PDF Initiate and Extend Opposing Behavioral 
States in C. elegans. Cell. 2013;154(5):1023–1035. 
doi:10.1016/j.cell.2013.08.001 
40. Iwanir S, Tramm N, Nagy S, Wright C, Ish D, Biron D. The microarchitecture 
of C. elegans behavior during lethargus: homeostatic bout dynamics, a typical 
body posture, and regulation by a central neuron. Sleep. 2013;36(3):385–395. 
41. Zheng S-Q, Ding A-J, Li G-P, Wu G-S, Luo H-R. Drug absorption efficiency 
in Caenorhabditis elegans delivered by different methods. PloS one. 2013;8(2). 
42. Solis GM, Petrascheck M. Measuring Caenorhabditis elegans life span in 96 
well microtiter plates. JoVE (Journal of Visualized Experiments). 
2011;(49):e2496. 
43. Kaletta T, Hengartner MO. Finding function in novel targets: C. elegans as a 
model organism. Nature reviews Drug discovery. 2006;5(5):387–399. 
44. Stawicki TM, Zhou K, Yochem J, Chen L, Jin Y. TRPM channels modulate 
epileptic-like convulsions via systemic ion homeostasis. Current Biology. 
2011;21(10):883–888. 
45. Perkins LA, Hedgecock EM, Thomson JN, Culotti JG. Mutant sensory cilia in 
the nematode Caenorhabditis elegans. Developmental biology. 1986;117(2):456–
487. 
 26 
46. Pirillo A, Catapano AL. Berberine, a plant alkaloid with lipid- and glucose-
lowering properties: From in vitro evidence to clinical studies. Atherosclerosis. 
2015;243(2):449–461. doi:10.1016/j.atherosclerosis.2015.09.032 
47. Lee S, Lim H-J, Park H-Y, Lee K-S, Park J-H, Jang Y. Berberine inhibits rat 
vascular smooth muscle cell proliferation and migration in vitro and improves 
neointima formation after balloon injury in vivo: berberine improves neointima 
formation in a rat model. Atherosclerosis. 2006;186(1):29–37. 
48. Cho B-J, Im EK, Kwon JH, Lee K-H, Shin H-J, Oh J, Kang S-M, Chung JH, 
Jang Y. Berberine inhibits the production of lysophosphatidylcholine-induced 
reactive oxygen species and the ERK1/2 pathway in vascular smooth muscle 
cells. 2005. 
49. Li Z, Geng Y-N, Jiang J-D, Kong W-J. Antioxidant and anti-inflammatory 
activities of berberine in the treatment of diabetes mellitus. Evidence-Based 
Complementary and Alternative Medicine. 2014;2014. 
50. Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, Wang Y, Wang Z, Si S, Pan 
H, et al. Berberine is a novel cholesterol-lowering drug working through a unique 
mechanism distinct from statins. Nature Medicine. 2004;10(12):1344–1351. 
doi:10.1038/nm1135 
51. Yin J, Gao Z, Liu D, Liu Z, Ye J. Berberine improves glucose metabolism 
through induction of glycolysis. American Journal of Physiology-Endocrinology 
and Metabolism. 2008;294(1):E148–E156. 
52. Choi MS, Yuk DY, Oh JH, Jung HY, Han SB, Moon DC, Hong JT. Berberine 
inhibits human neuroblastoma cell growth through induction of p53-dependent 
apoptosis. Anticancer research. 2008;28(6A):3777–3784. 
53. Crowther D, Kinghorn K, Miranda E, Page R, Curry J, Duthie F, Gubb D, 
Lomas D. Intraneuronal Aβ, non-amyloid aggregates and neurodegeneration in a 
Drosophila model of Alzheimer’s disease. Neuroscience. 2005;132(1):123–135. 
54. Sun Y, Xia M, Yan H, Han Y, Zhang F, Hu Z, Cui A, Ma F, Liu Z, Gong Q, 
et al. Berberine attenuates hepatic steatosis and enhances energy expenditure in 
mice by inducing autophagy and fibroblast growth factor 21. British Journal of 
Pharmacology. 2018;175(2):374–387. doi:10.1111/bph.14079 
55. Yang S-S, Yu C-B, Luo Z, Luo W-L, Zhang J, Xu J-X, Xu W-N. Berberine 
attenuates sodium palmitate-induced lipid accumulation, oxidative stress and 
apoptosis in grass carp (Ctenopharyngodon idella) hepatocyte in vitro. Fish & 
Shellfish Immunology. 2019;88:518–527. doi:10.1016/j.fsi.2019.02.055 
 
 27 
56. Wang Y, Yi X, Ghanam K, Zhang S, Zhao T, Zhu X. Berberine decreases 
cholesterol levels in rats through multiple mechanisms, including inhibition of 
cholesterol absorption. Metabolism. 2014;63(9):1167–1177. 
doi:10.1016/j.metabol.2014.05.013 
57. Hu Y, Davies GE. Berberine inhibits adipogenesis in high-fat diet-induced 
obesity mice. Fitoterapia. 2010;81(5):358–366. doi:10.1016/j.fitote.2009.10.010 
58. Kong W-J, Wei J, Zuo Z-Y, Wang Y-M, Song D-Q, You X-F, Zhao L-X, Pan 
H-N, Jiang J-D. Combination of simvastatin with berberine improves the lipid-
lowering efficacy. Metabolism. 2008;57(8):1029–1037. 
doi:10.1016/j.metabol.2008.01.037 
59. Liu C, Wang Z, Song Y, Wu D, Zheng X, Li P, Jin J, Xu N, Li L. Effects of 
Berberine on Amelioration of Hyperglycemia and Oxidative Stress in High 
Glucose and High Fat Diet-Induced Diabetic Hamsters In Vivo. BioMed Research 
International. 2015;2015:1–9. doi:10.1155/2015/313808 
60. Chang X, Yan H, Xu Q, Xia M, Bian H, Zhu T, Gao X. The effects of 
berberine on hyperhomocysteinemia and hyperlipidemia in rats fed with a long-
term high-fat diet. Lipids in Health and Disease. 2012;11(1):86. 
doi:10.1186/1476-511x-11-86 
61. Krishan S, Richardson DR, Sahni S. Adenosine monophosphate–activated 
kinase and its key role in catabolism: Structure, regulation, biological activity, and 
pharmacological activation. Molecular pharmacology. 2015;87(3):363–377. 
62. Ni W-J, Ding H-H, Tang L-Q. Berberine as a promising anti-diabetic 
nephropathy drug: An analysis of its effects and mechanisms. European Journal of 
Pharmacology. 2015;760:103–112. doi:10.1016/j.ejphar.2015.04.017 
63. Zhang B, Pan Y, Xu L, Tang D, Dorfman RG, Zhou Q, Yin Y, Li Y, Zhou L, 
Zhao S, et al. Berberine promotes glucose uptake and inhibits gluconeogenesis by 
inhibiting deacetylase SIRT3. Endocrine. 2018;62(3):576–587. 
doi:10.1007/s12020-018-1689-y 
64. Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, Shen Y, Ye J-M, Lee CH, Oh 
WK, Kim CT, et al. Berberine, a Natural Plant Product, Activates AMP-Activated 
Protein Kinase With Beneficial Metabolic Effects in Diabetic and Insulin-
Resistant States. Diabetes. 2006;55(8):2256–2264. doi:10.2337/db06-0006 
65. Zhao H-L, Sui Y, Qiao C-F, Yip KY, Leung RKK, Tsui SKW, Lee H-M, 
Wong HKT, Zhu X, Siu JJ, et al. Sustained Antidiabetic Effects of a Berberine-
Containing Chinese Herbal Medicine Through Regulation of Hepatic Gene 
Expression. Diabetes. 2012;61(4):933–943. doi:10.2337/db11-1164 
 
 28 
66. Kulkarni S, Dhir A. Berberine: a plant alkaloid with therapeutic potential for 
central nervous system disorders. Phytotherapy Research: An International 
Journal Devoted to Pharmacological and Toxicological Evaluation of Natural 
Product Derivatives. 2010;24(3):317–324. 
67. Tillhon M, Ortiz LMG, Lombardi P, Scovassi AI. Berberine: new perspectives 
for old remedies. Biochemical pharmacology. 2012;84(10):1260–1267. 
68. Xu Z, Feng W, Shen Q, Yu N, Yu K, Wang S, Chen Z, Shioda S, Guo Y. 
Rhizoma Coptidis and Berberine as a Natural Drug to Combat Aging and Aging-
Related Diseases via Anti-Oxidation and AMPK Activation. Aging and Disease. 
2017;8(6):760. doi:10.14336/ad.2016.0620 
69. Winder W, Holmes B, Rubink D, Jensen E, Chen M, Holloszy J. Activation of 
AMP-activated protein kinase increases mitochondrial enzymes in skeletal 
muscle. Journal of applied physiology. 2000;88(6):2219–2226. 
70. Ojuka EO. Role of calcium and AMP kinase in the regulation of 
mitochondrial biogenesis and GLUT4 levels in muscle. Proceedings of the 
Nutrition Society. 2004;63(2):275–278. 
71. Jia J, Bissa B, Brecht L, Allers L, Choi SW, Gu Y, Zbinden M, Burge MR, 
Timmins G, Hallows K. AMPK, a Regulator of Metabolism and Autophagy, Is 
Activated by Lysosomal Damage via a Novel Galectin-Directed Ubiquitin Signal 
Transduction System. Molecular Cell. 2020. 
72. Zhang C-S, Li M, Ma T, Zong Y, Cui J, Feng J-W, Wu Y-Q, Lin S-Y, Lin S-
C. Metformin activates AMPK through the lysosomal pathway. Cell metabolism. 
2016;24(4):521–522. 
73. Colmenares D, Sun Q, Shen P, Yue Y, McClements DJ, Park Y. Delivery of 
dietary triglycerides to Caenorhabditis elegans using lipid nanoparticles: 
Nanoemulsion-based delivery systems. Food Chemistry. 2016;202:451–457. 
doi:10.1016/j.foodchem.2016.02.022 
74. Braeckman BP, Houthoofd K, Vreese AD, Vanfleteren JR. Assaying 
metabolic activity in ageing Caenorhabditis elegans. Mechanisms of ageing and 
development. 2002;123(2–3):105–119. 
75. Houthoofd K, Braeckman BP, Lenaerts I, Brys K, Vreese AD, Eygen SV, 
Vanfleteren JR. No reduction of metabolic rate in food restricted Caenorhabditis 
elegans. Experimental gerontology. 2002;37(12):1359–1369. 
76. Baugh LR. To Grow or Not to Grow: Nutritional Control of Development 
During Caenorhabditis elegans L1 Arrest. Genetics. 2013;194(3):539–555. 
doi:10.1534/genetics.113.150847 
 29 
77. Hubbard EJA, Greenstein D. The Caenorhabditis elegans gonad: a test tube 
for cell and developmental biology. Developmental dynamics: an official 
publication of the American Association of Anatomists. 2000;218(1):2–22. 
78. Apfeld J, O’Connor G, McDonagh T, DiStefano PS, Curtis R. The AMP-
activated protein kinase AAK-2 links energy levels and insulin-like signals to 
lifespan in C. elegans. Genes & development. 2004;18(24):3004–3009. 
79. Peng Y, Sun Q, Gao R, Park Y. AAK-2 and SKN-1 Are Involved in Chicoric-
Acid-Induced Lifespan Extension in Caenorhabditis elegans. Journal of 
Agricultural and Food Chemistry. 2019;67(33):9178–9186. 
doi:10.1021/acs.jafc.9b00705 
80. Baugh LR, Sternberg PW. DAF-16/FOXO regulates transcription of cki-
1/Cip/Kip and repression of lin-4 during C. elegans L1 arrest. Current Biology. 
2006;16(8):780–785. 
81. Wählby C, Conery AL, Bray M-A, Kamentsky L, Larkins-Ford J, Sokolnicki 
KL, Veneskey M, Michaels K, Carpenter AE, O’Rourke EJ. High-and low-
throughput scoring of fat mass and body fat distribution in C. elegans. Methods. 
2014;68(3):492–499. 
82. Shen P, Yue Y, Kim K-H, Park Y. Piceatannol Reduces Fat Accumulation in 
Caenorhabditis elegans. Journal of Medicinal Food. 2017;20(9):887–894. 
doi:10.1089/jmf.2016.0179 
 
